• CSS Log In
  • Language
  • Transcriptome Sequencing
  • Eukaryote
  • mRNA Sequencing
  • Non-coding RNA Sequencing
  • Long non-coding RNA Sequencing
  • Small RNA Sequencing
  • Circular RNA Sequencing
  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics
  • Whole Genome Bisulfite Sequencing (Gene Methylation)
  • Reduced Representation Bisulfite Sequencing (RRBS-Gene Methylation)
  • ChIP-Seq
  • RIP-Seq
  • Metagenomics
  • 16S/18S/ITS Amplicon Metagenomic Sequencing
  • Shotgun Metagenomic Sequencing
  • Pre-made Library Sequencing
  • Pre-made Library Sequencing
  • Clinical Diagnostics
  • Clinical Whole Exome Sequencing (CLIA/CAP)
  • Clinical Panels
  • Genetic Testing
  • Oncology
  • NovoPM™ 2.0
  • NovoFocus™ NSCLC 2.0
  • NovoFocus™ CRC 2.0
  • NovoFocus™ PARPi CDx 1.0
  • NovoFocus™ CR
  • Cancer Immunotherapy Biomarkers
  • Patient's Case Study
  • Biopharma Services
  • Discovery and Pre Clinical
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • RNA-Seq
  • FFPE RNA-seq
  • Small RNA Sequencing
  • Pacbio Sequencing (DNA)
  • Pacbio Sequencing (RNA)
  • Pre-made Library Sequencing
  • Translational and Clinical
  • NovoPM™ 2.0
  • NovoNeoantigen™ 2.0
  • Star Allele Analysis
  • Tumor Microenvironment Analysis
  • Companion Diagnostics
  • Service Support
  • Service Workflow
  • Sample Preparation Guide
  • Sample Requirements
  • Quality Management
  • Data Analysis
  • FAQs​​
  • Technology
  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Resources
  • Publications
  • Downloads
  • Brochure/Magazine
  • Webinars
  • About
  • About Us
  • Major Milestones
  • Careers
  • News & Events
  • Partnership
  • Contact Us
  • De novo Sequencing
  • Animal & Plant De novo Sequencing
  • Microbial De novo Sequencing
  • Transcriptome Sequencing

  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics

    Metagenomics

    Pre-made Library Sequencing

  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Publications
  • Downloads
  • Brochure/Magazine
  • Webinars
  • About Us
  • Major Milestones
  • Careers
  • News & Events
  • Partnership
  • Tell us about your project
    Contact us to discuss how we can help you achieve your research goals
    Biopharma Services

    Tumor Microenvironment Analysis

    The Background of Tumor Microenvironment

    Tumor microenvironment (TME) is the environment around a tumor that is composed of extracellular matrix (ECM), stromal cells (fibroblasts, mesenchymal stromal cells, pericytes, occasionally adipocytes, blood, and lymphatic vascular networks), and immune cells (T and B lymphocytes, natural killer cells, and Tumor-associated macrophages). The recent clinical success of immune checkpoint inhibitors (ICIs) in treating several different types of cancer has raised the interest of TME at the genetic and phenotypic levels. Understanding the interaction between tumor cells and their microenvironment furthers our knowledge of the molecular mechanisms involved in tumor formation and facilitates immune-oncology drug development.

    Advantages
  • State-of-the-art NGS technologies: Novogene is a world leader in sequencing capacity using state-of-the-art technology, including Illumina HiSeq and NovaSeq 6000 Systems.
  • Unsurpassed data quality: Guarantee of a Q30 score ≥ 80%, exceeding Illumina‘s official guarantee of ≥ 75%.
  • Extraordinary informatics expertise: Cutting-edge bioinformatics pipeline and internationally recognized best-in-class software, with professional bioinformatics team to support customized analysis tailored to clients’ requirements.
  • Short turn-around time: Variable upon different requirements.
  • Tumor Microenvironment Analysis by RNA-seq in Novogene

    Novogene is a leading provider of genomic services and solutions with cutting-edge NGS platforms and bioinformatics expertise. Novogene, using RNA sequencing (RNA-seq), can provide a highly comprehensive tumor microenvironment analysis at a highly competitive price. Novogene can also support customized analysis with our professional bioinformatics team.

    Analysis Contents

    Tumor immunoassay using transcriptome data can be used to score and evaluate the tumor microenvironment of the sample, and to study its relationship with prognostic survival and immunotherapy response alone or in combination with other indicators. In addition, it can refine the composition of tumor microenvironment, draw the map of tumor microenvironment, which can help depicting the mechanism of immune regulation.

  • Evaluation of tumor purity
  • Tumor gene signature analysis
  • Tumor microenvironment-related cell analysis
  • TCR analysis​
  • Novogene Data

    A paper[1] about breast cancer recently published in Cancer Epidemiology Biomarkers & Prevention by West China Hospital, Sichuan University and Novogene, Smith et. al included 76 patients with TNBC diagnosed between 2008 to 2016 in West China Hospital and 158 patients with TNBC from The Cancer Genome Atlas. On the basis of transcriptome data, we calculated the overall Immune-Score and type-specific enrichment scores for 34 types of immune cells, using xCell, a gene signature–based method. This findings suggest that plasma cells and CD4þTcm in the tumor microenvironment may play a role in the subsequent progression of TNBC. This study provides evidence of the role of immune cells in TNBC progression that may have clinicalutility. Download here.